Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 4
1976 1
1978 1
1979 1
1980 1
1981 2
1982 3
1983 1
1984 1
1985 3
1986 1
1987 2
1988 1
1989 3
1990 6
1991 4
1992 4
1993 6
1994 3
1995 4
1996 5
1997 13
1998 8
1999 6
2000 13
2001 12
2002 5
2003 7
2004 9
2005 5
2006 11
2007 15
2008 9
2009 12
2010 19
2011 20
2012 12
2013 20
2014 27
2015 17
2016 17
2017 20
2018 25
2019 22
2020 18
2021 24
2022 20
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

417 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Rhabdomyosarcoma, embryonal, 2"
Page 1
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, Ruhen O, Shern JF, Khan J, Kovach AR, Lupo PJ, Gatz SA, Schäfer BW, Volchenboum S, Minard-Colin V, Koscielniak E, Hawkins DS, Bisogno G, Sparber-Sauer M, Venkatramani R, Merks JHM, Shipley J. Hettmer S, et al. Eur J Cancer. 2022 Sep;172:367-386. doi: 10.1016/j.ejca.2022.05.036. Epub 2022 Jul 12. Eur J Cancer. 2022. PMID: 35839732 Free article. Review.
Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence of 1-2/million. Inter/intra-tumour heterogeneity raise challenges in clinical, pathological and biological research studies. ...In p …
Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence …
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Crist WM, et al. J Clin Oncol. 2001 Jun 15;19(12):3091-102. doi: 10.1200/JCO.2001.19.12.3091. J Clin Oncol. 2001. PMID: 11408506 Clinical Trial.
CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously. Younger patients with group 1 paratesticular e …
CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarc …
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A; European paediatric Soft tissue sarcoma Study Group. Bisogno G, et al. Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24. Lancet Oncol. 2019. PMID: 31562043 Clinical Trial.
METHODS: RMS 2005 was a multicentre, open-label, randomised, controlled, phase 3 trial done at 102 hospitals in 14 countries. We included patients aged 6 months to 21 years with rhabdomyosarcoma who were considered to be at high risk of relapse: those with non-metastatic i …
METHODS: RMS 2005 was a multicentre, open-label, randomised, controlled, phase 3 trial done at 102 hospitals in 14 countries. We included pa …
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Croce S, et al. Gynecol Oncol. 2022 Nov;167(2):373-389. doi: 10.1016/j.ygyno.2022.07.031. Epub 2022 Sep 14. Gynecol Oncol. 2022. PMID: 36114030 Review.
Uterine PEComa has a specific algorithm stratifying the tumors into uncertain malignant potential and malignant tumors. Embryonal rhabdomyosarcomas of the uterine cervix are not restricted to children but can also be observed in adult women and are almost always DICER1 mut …
Uterine PEComa has a specific algorithm stratifying the tumors into uncertain malignant potential and malignant tumors. Embryonal rha …
Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma.
DeMartino J, Meister MT, Visser LL, Brok M, Groot Koerkamp MJA, Wezenaar AKL, Hiemcke-Jiwa LS, de Souza T, Merks JHM, Rios AC, Holstege FCP, Margaritis T, Drost J. DeMartino J, et al. Nat Commun. 2023 May 27;14(1):3074. doi: 10.1038/s41467-023-38886-8. Nat Commun. 2023. PMID: 37244912 Free PMC article.
Paediatric rhabdomyosarcoma (RMS) is a soft tissue malignancy of mesenchymal origin that is thought to arise as a consequence of derailed myogenic differentiation. ...
Paediatric rhabdomyosarcoma (RMS) is a soft tissue malignancy of mesenchymal origin that is thought to arise as a consequence of dera …
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristin …
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with …
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. Spunt SL, et al. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786124 Free PMC article.
The treatment groups were surgery alone, radiotherapy (55.8 Gy), chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost based on margins with continued chemotherapy). C …
The treatment groups were surgery alone, radiotherapy (55.8 Gy), chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy), and neoadjuvant …
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group.
Martin-Giacalone BA, Richard MA, Scheurer ME, Khan J, Sok P, Shetty PB, Chanock SJ, Li SA, Yeager M, Marquez-Do DA, Barkauskas DA, Hall D, McEvoy MT, Brown AL, Sabo A, Scheet P, Huff CD, Skapek SX, Hawkins DS, Venkatramani R, Mirabello L, Lupo PJ. Martin-Giacalone BA, et al. J Natl Cancer Inst. 2023 Jun 8;115(6):733-741. doi: 10.1093/jnci/djad055. J Natl Cancer Inst. 2023. PMID: 36951526 Free PMC article.
RESULTS: We identified that rs17321084 was associated with worse EFS (HR = 2.01, 95% CI = 1.59 to 2.53, P = 5.39 10-9) and rs10094840 was associated with worse OS (HR = 1.84, 95% CI = 1.48 to 2.27, P = 2.13 10-8). ...We also identified that CTNNA3 rs21 …
RESULTS: We identified that rs17321084 was associated with worse EFS (HR = 2.01, 95% CI = 1.59 to 2.53, P = 5.39 10-9) and rs1 …
Recent advances in pediatric bladder malignancies.
Lopes RI, Mello MF, Lorenzo AJ. Lopes RI, et al. F1000Res. 2020 Feb 25;9:F1000 Faculty Rev-147. doi: 10.12688/f1000research.19396.1. eCollection 2020. F1000Res. 2020. PMID: 32148770 Free PMC article. Review.
Papillary urothelial neoplasms of low malignant potential (PUNLMPs) and rhabdomyosarcoma (RMS) are the most common bladder malignancies in the pediatric population. ...Deriving from the embryonic mesenchymal cell, the histopathologic subtypes of RMS are embryonal RM …
Papillary urothelial neoplasms of low malignant potential (PUNLMPs) and rhabdomyosarcoma (RMS) are the most common bladder malignanci …
Molecular diagnostics in the management of rhabdomyosarcoma.
Arnold MA, Barr FG. Arnold MA, et al. Expert Rev Mol Diagn. 2017 Feb;17(2):189-194. doi: 10.1080/14737159.2017.1275965. Epub 2017 Jan 6. Expert Rev Mol Diagn. 2017. PMID: 28058850 Free PMC article. Review.
A classification of rhabdomyosarcoma (RMS) with prognostic relevance has primarily relied on clinical features and histologic classification as either embryonal or alveolar RMS. ...
A classification of rhabdomyosarcoma (RMS) with prognostic relevance has primarily relied on clinical features and histologic classif …
417 results